Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban vs Clopidogrel in Recent Stroke/TIA with ICAS (AA-ICAS)
NCT05700266Phase 3Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of rivaroxaban in ischemic stroke and Transient Ischemic Attack (TIA) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Any stroke (ischemic or hemorrhagic) or death at 1 year. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
rivaroxaban
03
Conditions
ischemic strokeTransient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT05700266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05700266.